Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C
Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV)
